[go: up one dir, main page]

US20050043324A1 - Polymorphic forms of ziprasidone HCI and processes for their preparation - Google Patents

Polymorphic forms of ziprasidone HCI and processes for their preparation Download PDF

Info

Publication number
US20050043324A1
US20050043324A1 US10/860,926 US86092604A US2005043324A1 US 20050043324 A1 US20050043324 A1 US 20050043324A1 US 86092604 A US86092604 A US 86092604A US 2005043324 A1 US2005043324 A1 US 2005043324A1
Authority
US
United States
Prior art keywords
ziprasidone
hcl
crystalline form
ziprasidone hcl
slurry
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/860,926
Other languages
English (en)
Inventor
Tamas Koltai
Lilach Hedvati
Marioara Mendelovici
Tamar Nidam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/860,926 priority Critical patent/US20050043324A1/en
Assigned to TEVA PHARMACEUTICAL INDUSTRIES LTD. reassignment TEVA PHARMACEUTICAL INDUSTRIES LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HEDVATI, LILACH, KOLTAI, TAMAS, NIDAM, TAMAR, MENDELOVICI, MARIOARA
Assigned to TEVA PHARMACEUTICALS USA, INC. reassignment TEVA PHARMACEUTICALS USA, INC. ASSIGNMENT OF RIGHTS IN BARBADOS Assignors: TEVA PHARMACEUTICAL INDUSTRIES LTD.
Publication of US20050043324A1 publication Critical patent/US20050043324A1/en
Priority to US11/999,453 priority patent/US20080091020A1/en
Priority to US11/999,337 priority patent/US20080090835A1/en
Assigned to TEVA PHARMACEUTICAL INDUSTRIES LTD. reassignment TEVA PHARMACEUTICAL INDUSTRIES LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HEDVATI, LILACH, KOLTAI, TAMAS, NIDAM, TAMAR, MENDELOVICI, MARIOARA
Assigned to TEVA PHARMACEUTICAL INDUSTRIES LTD. reassignment TEVA PHARMACEUTICAL INDUSTRIES LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HEDVATI, LILACH, KOLTAI, TAMAS, NIDAM, TAMAR, MENDELOVICI, MARIOARA
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Definitions

  • the present invention relates to the solid state chemistry of ziprasidone HCl.
  • Ziprasidone is an antipsychotic agent that is chemically unrelated to phenothiazine or butyrophenone antipsychotic agents. Ziprasidone has the following structure:
  • ziprasidone base is disclosed in U.S. Pat. No. 4,831,031 (example 16). Preparation of ziprasidone base is also disclosed in U.S. Pat. No. 5,312,925. A process for preparation of ziprasidone HCl monohydrate having a mean particle size equal to or less than about 85 microns is also disclosed in U.S. Pat. No. 6,150,366 and EP 0 965 343 A2.
  • Ziprasidone has been marketed under the name GEODON as an oral capsule and as an injectable drug.
  • GEODON capsules contain the monohydrate hydrochloride salt of ziprasidone, and come in 20, 40, 60 and 80 mg dosage forms.
  • GEODON for injection contains a lyophilized form of ziprasidone mesylate trihydrate, and contains 20 mg base equivalent of ziprasidone.
  • the mesylate salts of ziprasidone, including monohydrate and trihydrate, are disclosed in U.S. Pat. Nos. 6,110,918 and 5,245,765.
  • the present invention relates to the solid state physical properties of ziprasidone HCl. These properties can be influenced by controlling the conditions under which ziprasidone HCl is obtained in solid form.
  • Solid state physical properties include, for example, the flowability of the milled solid. Flowability affects the ease with which the material is handled during processing into a pharmaceutical product. When particles of the powdered compound do not flow past each other easily, a formulation specialist must take that fact into account in developing a tablet or capsule formulation, which may necessitate the use of glidants such as colloidal silicon dioxide, talc, starch or tribasic calcium phosphate.
  • Another important solid state property of a pharmaceutical compound is its rate of dissolution in aqueous fluid.
  • the rate of dissolution of an active ingredient in a patient's stomach fluid can have therapeutic consequences since it imposes an upper limit on the rate at which an orally-administered active ingredient can reach the patient's bloodstream.
  • the rate of dissolution is also a consideration in formulating syrups, elixirs and other liquid medicaments.
  • the solid state form of a compound may also affect its behavior on compaction and its storage stability.
  • a particular polymorphic form may give rise to distinct spectroscopic properties that may be detectable by powder X-Ray diffraction, solid state 13 C NMR spectrometry and infrared spectrometry.
  • the polymorphic form may also give rise to thermal behavior different from that of the amorphous material or another polymorphic form. Thermal behavior is measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) and can be used to distinguish some polymorphic forms from others.
  • Ziprasidone HCl hemihydrate is disclosed in U.S. Pat. No. 4,831,031, Example 16 (column 13, line 13).
  • a ziprasidone HCl monohydrate (herein designated Form M) is disclosed in U.S. Pat. No. 5,312,925 and EP 0 586 181 A1.
  • Form M is characterized by XRD, IR and water content. It is reported that the water content of Form M ranges from 3.8 to 4.5% by weight.
  • Ziprasidone HCl Form M is prepared from ziprasidone base anhydrous.
  • the present invention provides a crystalline form of ziprasidone HCl (Form E), wherein the crystalline form is characterized by a powder XRD pattern with peaks at 7.4, 13.0, 20.7, 23.4, 25.9 ⁇ 0.2 degrees 2 theta.
  • the present invention provides a process for preparing ziprasidone HCl Form E, comprising:
  • the present invention provides a crystalline form of ziprasidone HCl, wherein the crystalline form is a trihydrate.
  • the present invention provides a process for preparing ziprasidone HCl Form E in a mixture with a crystalline ziprasidone HCl having an X-Ray diffraction pattern having peaks at about 10.9, 17.4 and 19.1 ⁇ 0.2 degrees 2 theta, comprising:
  • the present invention provides a crystalline form of ziprasidone HCl (Form F), wherein the crystalline form is characterized by a powder XRD pattern with peaks at 11.0, 18.1, 19.5, 21.9 ⁇ 0.2 degrees 2 theta.
  • the present invention provides a process for preparing the ziprasidone HCl Form F, comprising:
  • the present invention provides a process for preparing the ziprasidone HCl form M, comprising:
  • the present invention provides a process for preparing the ziprasidone HCl form M comprising:
  • the present invention provides a process for preparing the ziprasidone HCl form M comprising:
  • the present invention provides a process for preparing the ziprasidone HCl form M substantially free of the crystalline ziprasidone HCl characterized by a powder XRD pattern with peaks at 10.9, 17.4, 19.1, 25.0, 26.0 ⁇ 0.2 degrees 2 theta comprising:
  • the present invention provides for amorphous form of ziprasidone HCl.
  • the present invention provides a process for preparing amorphous form comprising slurrying ziprasidone base with methyl ethyl ketone or mono-chloro benzene with gaseous hydrochloride.
  • the present invention provides a crystalline form of ziprasidone HCl (Form G), wherein the crystalline form is characterized by a powder XRD pattern with peaks at 9.0, 20.6, 22.7, 25.0, 27.0 ⁇ 0.2 degrees 2 theta.
  • the present invention provides a process for preparing ziprasidone HCl Form G comprising:
  • the present invention provides a process for preparing a mixture of the ziprasidone HCl of Form F and ziprasidone HCl Form G comprising:
  • the present invention provides a crystalline form of ziprasidone HCl (Form I), wherein the crystalline form has an XRD pattern with peaks at 15.8, 16.2, 18.9, 23.8, 27.0 ⁇ 0.2 degrees 2 theta,
  • the present invention provides a crystalline form of ziprasidone HCl (Form J), wherein the crystalline form is characterized by a powder XRD pattern with peaks at 9.1, 19.1, 25.7, 26.3, 26.9 ⁇ 0.2 degrees 2 theta.
  • the present invention provides a process for preparing ziprasidone HCl Form J comprising:
  • the present invention provides a crystalline form of ziprasidone HCl, wherein the crystalline form has a water content of about 24% by LOD.
  • the present invention provides a crystalline from of ziprasidone HCl (Form E1), wherein the crystalline form is characterized a powder XRD pattern with peaks at 7.5, 13.0, 21.2, 23.4 and 26.0 ⁇ 0.2 degrees 2 theta.
  • the present invention provides a process for preparing ziprasidone HCl Form E1 comprising drying the ziprasidone HCl Form J.
  • the present invention provides a crystalline form of ziprasidone, wherein the crystalline form has a water content of about 6% to about 8%.
  • the present invention provides a pharmaceutical composition and method of treating a patient suffering from schizophrenia.
  • FIG. 1 is an X-Ray powder diffractogram of amorphous ziprasidone HCl.
  • FIG. 2 is a DSC thermogram of amorphous ziprasidone HCl.
  • FIG. 3 is an IR spectrum of ziprasidone HCl amorphous.
  • FIG. 4 is an X-Ray powder diffractogram of ziprasidone HCl form E.
  • FIG. 5 is a DSC thermogram of ziprasidone HCl form E.
  • FIG. 6 is an IR spectrum of ziprasidone HCl form E.
  • FIG. 7 is an X-Ray powder diffractogram of ziprasidone HCl form F.
  • FIG. 8 is a DSC thermogram of ziprasidone HCl form F.
  • FIG. 9 is an IR spectrum of ziprasidone HCl form F.
  • FIG. 10 is a DSC thermogram of ziprasidone HCl Form M.
  • FIG. 11 is an IR spectrum of ziprasidone HCl Form M.
  • FIG. 12 is an X-Ray powder diffractogram of ziprasidone Base.
  • FIG. 13 is a DSC thermogram of ziprasidone Base.
  • FIG. 14 is an IR spectrum of ziprasidone Base.
  • FIG. 15 is an X-Ray powder diffractogram of ziprasidone HCl Form G.
  • FIG. 16 is an X-Ray powder diffractogram of ziprasidone HCl Form I.
  • FIG. 17 is an X-Ray powder diffractogram of ziprasidone HCl Form J.
  • FIG. 18 is an FTIR spectrum of ziprasidone HCl Form J.
  • FIG. 19 is an FTIR spectrum of ziprasidone HCl Form J.
  • FIG. 20 is an FTIR spectrum of ziprasidone HCl Form J.
  • FIG. 21 is an X-Ray powder diffractogram of ziprasidone HCl Form E1.
  • FIG. 22 is an FTIR spectrum of ziprasidone HCl Form E1.
  • FIG. 23 is an FTIR spectrum of ziprasidone HCl Form E1.
  • FIG. 24 is an FTIR spectrum of ziprasidone HCl Form E1.
  • slurry refers to a heterogeneous mixture.
  • reduced pressure refers to a pressure below about 1 atm, more preferably below about 100 mmHg.
  • the present invention provides for obtaining ziprasidone HCl Form M from ziprasidone base, or other forms of ziprasidone hydrochloride.
  • Ziprasidone base such as form B, but not limited to this form, is combined with aqueous hydrochloric acid and slurried in solvents such as methanol, ethanol, n-butanol, ethyl acetate, ethyl lactate, acetone, dimethyl carbonate, optionally in mixtures with water.
  • Gaseous hydrogen chloride may be used with methanol.
  • the slurry is then allowed to last for a sufficient amount of time (maintained) to obtain the monohydrate, preferably for about half a day.
  • the slurry process is preferably carried out about room temperature to about reflux temperature of the solvents.
  • Preferred combination of starting bases and solvents include Form B and ethyl acetate/ethanol/methanol/n-butanol.
  • another polymorphic form of ziprasidone HCl is used for the slurry process.
  • Preferred combination of solvents and starting forms include ziprasidone HCl Form F and THF and ziprasidone HCl Form E and n-butanol, preferably in mixtures with water.
  • the slurry is heated for a sufficient amount of time, more preferably to at least about 40° C.
  • the present invention also provides a process for preparation of Form M, but in a substantially pure form, by slow crystallization from slurry or solution of ziprasidone base in an organic solvent.
  • Preferred solvents are mixtures of THF/AcOH, THF/MeOH, DMA, n-BuOH/AcOH.
  • the temperature of crystallization is more than about 50° C., preferably of about 55 to about 70° C., more preferably about 55 to about 65° C., and most preferably 65 ⁇ 2° C.
  • the mode of HCl addition is preferably portion-wise.
  • a first portion of HCl is added until opalescence is obtained, and the mixture is stirred to induce nucleation, followed by the rest of HCl addition.
  • opalescence resulting from formation of ziprasidone HCl is observed after adding ⁇ fraction (1/10) ⁇ portion of the HCl. Seeding of ziprasidone base before the HCl addition is ideal.
  • the present invention provides for ziprasidone HCl Form E.
  • Ziprasidone HCl Form E is characterized by an X-Ray diffraction pattern ( FIG. 4 ) with peaks at 7.4, 13.0, 20.7, 23.4, 25.9 ⁇ 0.2 degrees 2 theta.
  • Ziprasidone HCl Form E is further characterized by XRD peaks at 13.7, 20.0, 21.3, 25.2 ⁇ 0.2 degrees two-theta.
  • the DSC thermogram of ziprasidone HCl Form E ( FIG. 5 ) shows endothermic peaks of about 22, 152 and 11 J/g at about 54, 94 and 132° C. respectively, which correspond to the desolvation and dehydration of ziprasidone HCl Form E.
  • the melting and decomposition of ziprasidone HCl Form E starts at about 280° C.
  • the water content of ziprasidone form E measured by Karl Fisher, ranges about 9.3% to about 9.6% by weight, and the weight loss measured by TGA is about 19% by weight. This corresponds approximately to a trihydrate, which may contain solvent approximately as 11 ⁇ 2-11 ⁇ 3 solvate of acetonitrile, or 2 ⁇ 3-3 ⁇ 4 solvate of ethyl acetate.
  • the FTIR spectrum of ziprasidone HCl form E is shown in FIG. 6 .
  • Ziprasidone HCl Form E when exposed to a high relative humidity, such as for about 22 days, transforms to form M. Ziprasidone HCl form E transforms
  • Ziprasidone HCl Form E transforms to Form A when exposed to a relative humidity of about 20% to about 60% for about 22 days (see table 1 and 2).
  • Form A is characterized by an X-Ray diffraction pattern having peaks at about 10.9, 17.4 19.1, 25.0 and 26.0 ⁇ 0.2 degrees 2 theta.
  • Ziprasidone HCl novel form E may be prepared by combining ziprasidone base with aqueous HCl in acetonitrile or ethyl acetate to obtain a slurry, and allowing the slurry to last for a sufficient time to obtain Form E.
  • the slurry process is preferably carried out overnight.
  • the combining of HCl with ziprasidone base is preferably carried out at a temperature of about 40° C. to about 60° C., with about 50° C. being preferred.
  • the slurrying after the combining is preferably carried out at a temperature of about 20° C. to about 30° C., more preferably at about room temperature.
  • Ziprasidone Form E may also be obtained as a mixture with Form A by a slurry process that uses tetrahydrofuran as a solvent. Slurrying at room temperature results in the mixture, while slurrying at higher temperatures, such as above about 50° C. results substantially in Form A.
  • TABLE NO. 1 Water uptake (%) and crystal form of ziprasidone HCl form E equilibrated at different relative humidities for 22 days RH (%) TGA weight loss (%) Crystal form 0 5.3 Amorphous 20 7.2 A 40 4.8 A 60 5.0 A 80 9.2 Monohydrate + A 100 51.3 Monohydrate + A + amorphous
  • the present invention provides for ziprasidone HCl Form F.
  • Ziprasidone HCl Form F is characterized by an XRD pattern ( FIG. 7 ) with peaks at 11.0, 18.1, 19.5, 21.9 ⁇ 0.2 degrees 2 theta.
  • Ziprasidone HCl Form F is further characterized by XRD peaks at 14.9, 24.9, 26.1 ⁇ 0.2 degrees 2 theta.
  • Ziprasidone HCl Form F has a DSC thermogram ( FIG. 8 ) which shows an about a 71 J/g endothermic peak at about 85° C., corresponding to the dehydration of the ziprasidone HCl Form F. At about 280° C., ziprasidone HCl Form F starts to melt and decompose.
  • the water content and the weight loss by TGA of the sample may range of about 2.6% to about 16% by weight.
  • ziprasidone HCl Form F When ziprasidone HCl Form F is equilibrated at relative humidity of about 0% to about 100%, it retains its crystal form. Ziprasidone HCl Form F, after being heated overnight at about 80° C., has very low water content (0.8%), but still retains its original crystal form (see tables 3 and 4). In the range of relative humidity of about 20% to about 60%, the water content equilibrates around about 4.0% to about 4.5%, which indicates that Form F may be a stable monohydrate when kept in the humidity range of about 20% to about 60% RH.
  • Ziprasidone HCl novel Form F may be prepared by combining ziprasidone base with aqueous HCl in tetrahydrofuran, methylethylketone or dimethylacetamide to obtain a slurry, and allowing the slurry to last for a sufficient time to obtain Form F.
  • the slurry may be diluted by addition of water.
  • the combining step is preferably carried out at elevated temperature, more preferably of about 50° C. to about 70° C., most preferably at about 60° C.
  • the slurrying after the combining is preferably carried out at a temperature of about 20° C. to about 30° C., more preferably at about room temperature.
  • Form F may be used for the preparation of Form M, by combining ziprasidone HCl Form F, THF and water, heating the slurry to about 50° C., cooling the slurry to room temperature, and maintaining for a sufficient time to obtain Form M.
  • the present invention provides for amorphous form of ziprasidone HCl.
  • Amorphous ziprasidone HCl has an X-Ray diffraction pattern as substantially depicted in FIG. 1 , in which reflection peaks are absent (halo-like pattern). Endothermic peaks are absent from the DSC thermogram of amorphous ziprasidone HCl ( FIG. 2 ).
  • the FTIR spectrum of amorphous ziprasidone HCl is substantially depicted in FIG. 3 .
  • Amorphous form of ziprasidone HCl may be prepared by placing Form E in a dessicator (dry chamber) having low humidity for a sufficient time to obtain amorphous form.
  • ziprasidone Form E is put in a dessicator having about 0% relative humidity for about 18 days.
  • Ziprasidone HCl amorphous may be prepared by drying ziprasidone HCl form E at an elevated temperature, preferably of about 80 to about 105° C., for a sufficient period of time, preferably of about 5 to about 30 hours, more preferably overnight ( ⁇ 15 hours). Ziprasidone HCl amorphous may also be prepared by exposing ziprasidone HCl form E to low relative humidity, preferably about 0%, for a sufficient period, preferably a time of about 1-3 weeks, more preferably for about 3 weeks.
  • Ziprasidone hydrochloride amorphous may also be prepared by treating the slurry of ziprasidone base in MEK or mono-chlorobenzene with gaseous HCl.
  • the present invention provides for ziprasidone HCl Form G.
  • Ziprasidone HCl Form G has an XRPD diffraction pattern with preferred peaks at 9.0, 20.6, 22.7, 25.0, 27.0 ⁇ 0.2 degrees 2 theta, and other peaks at 11.3, 12.5, 13.9, 15.6, 21.5, 23.5, 25.8, 28.0, 31.5 ⁇ 0.2 degrees two-theta.
  • Ziprasidone HCl Form G may have a water content of about 5% to about 12%. Ziprasidone HCl Form G may be a dihydrate (about 7.4% stochiometric value for the dihydrate) or a trihydrate (about 10.7% stochiometric value for the trihydrate). Ziprasidone HCl Form G is sparingly soluble in methanol, hence the water determination by Karl Fisher is carried out for more than 30 minutes in order to ensure that all the material is dissolved and all the water is analyzed.
  • Ziprasidone HCl Form G may be prepared by introducing HCl gas into a mixture of ziprasidone base in ethyl acetate, ethyl lactate, carbon tetrachloride, di-isopropyl-ether and mixtures thereof to obtain a slurry of ziprasidone HCl, and allowing the slurry to last for a sufficient time. The slurry is preferably stirred. When ethyl acetate is used in the absence of an ether, the result may be a mixture of Form G with Form F.
  • the resulting wet product may be separated by techniques known in the art such as filtration, and may be dried, preferably at a temperature of about 40° C. to about 60° C. for about half a day.
  • the present invention provides for ziprasidone HCl Form I.
  • Ziprasidone HCl Form I is characterized by an XRD pattern with peaks at 15.8, 16.2, 18.9, 23.8, 27.0 ⁇ 0.2 degrees 2 theta, and other peaks at 10.5, 11.3, 21.1, 24.8, 26.0 ⁇ 0.2 degrees two-theta.
  • Ziprasidone HCl Form I may be prepared by heating ziprasidone HCl Form G, preferably a ziprasidone Form G obtained from a slurry in di-iso-propyl ether. The heating is preferably carried out at a temperature of about 40° C. to about 60° C. for about half a day
  • the polymorphic forms of the present invention are preferably used with particle size up to 100 microns in light of low solubility of ziprasidone HCl in water.
  • Ziprasidone HCl anhydrous may be prepared by drying ziprasidone HCl Form M, for example by exposing the material to low relative humidity, preferably about 0% relative humidity, for a sufficient period, preferably for about 1-3 weeks, more preferably for about 3 weeks.
  • the present invention also provides for ziprasidone HCl form J.
  • Ziprasidone HCl Form J is characterized by XRD peaks at 9.1, 19.1, 25.7, 26.3, 26.9 ⁇ 0.2 degrees 2 theta, and other less characteristic peaks at 11.9, 21.4, 23.4, 30.7, 32.2 ⁇ 0.2 degrees two-theta.
  • Form J has an FTIR spectrum as substantially depicted in FIGS. 18 to 20 .
  • the present invention also provides for ziprasidone HCl Form J with a water content of about 24%.
  • Ziprasidone HCl Form J may be obtained by slurry of ziprasidone base in a C 5 to C 12 hydrocarbon, preferably toluene. A few hours of slurrying is sufficient after combining of HCl with ziprasidone base to obtain the slurry. Ziprasidone HCl Form J may then be recovered for example by solvent removal.
  • the present invention also provides for ziprasidone HCl Form E1.
  • Ziprasidone HCl Form E1 is characterized by XRD peaks at 7.5, 13.0, 21.2, 23.4 and 26.0 ⁇ 0.2 degrees 2 theta, and other less characteristic peaks at 10.9, 16.2, 20.8, 25.4, 30.3 and 34.8 ⁇ 0.2 degrees two-theta.
  • Ziprasidone HCl Form E1 has an FTIR spectrum as substantially depicted in FIGS. 22 to 24 .
  • the present invention also provides for ziprasidone HCl Form E1 with a water content of about 6% to about 8%.
  • Ziprasidone HCl Form E1 may be prepared by removing solvent from ziprasidone HCl Form J. Such removal may be done by drying Form J at elevated temperature, and/or under ambient or reduced pressure. A dry nitrogen atmosphere is preferred with a temperature of about 30° C. to about 50° C., with about 40° C. being preferred.
  • a slurry is most effective when the solids of the heterogeneous mixture are in substantial contact with the solvent.
  • the efficiency of the slurry process often decreases due to a decrease in contact.
  • a force such as stirring, agitating to disperse the solid.
  • Even when the solids have not settled down, bringing of movement in the solvent may even further increase the efficiency of the slurry process.
  • the slurry may dry up due to for example evaporation of the solvents.
  • additional amounts of a solvent may be added (same or different solvent), preferably followed by stirring, to obtain a slurry.
  • ziprasidone may be recovered from the slurry by conventional techniques in the art such as decanting, filtration and centrifugation.
  • compositions of the present invention contain crystalline ziprasidone HCl, such as one of those disclosed herein, or ziprasidone HCl amorphous, optionally in mixture with other form(s) of ziprasidone.
  • the pharmaceutical formulations of the present invention may contain one or more excipients. Excipients are added to the formulation for a variety of purposes.
  • Diluents increase the bulk of a solid pharmaceutical composition, and may make a pharmaceutical dosage form containing the composition easier for the patient and care giver to handle.
  • Diluents for solid compositions include, for example, microcrystalline cellulose (e.g. Avicel®), microfine cellulose, lactose, starch, pregelatinized starch, calcium carbonate, calcium sulfate, sugar, dextrates, dextrin, dextrose, dibasic calcium phosphate dihydrate, tribasic calcium phosphate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, mannitol, polymethacrylates (e.g. Eudragit®), potassium chloride, powdered cellulose, sodium chloride, sorbitol and talc.
  • microcrystalline cellulose e.g. Avicel®
  • microfine cellulose lactose
  • starch pregelatinized starch
  • calcium carbonate calcium sulfate
  • sugar dextrates
  • dextrin
  • Solid pharmaceutical compositions that are compacted into a dosage form, such as a tablet may include excipients whose functions include helping to bind the active ingredient and other excipients together after compression.
  • Binders for solid pharmaceutical compositions include acacia, alginic acid, carbomer (e.g. carbopol), carboxymethylcellulose sodium, dextrin, ethyl cellulose, gelatin, guar gum, hydrogenated vegetable oil, hydroxyethyl cellulose, hydroxypropyl cellulose (e.g. Klucel®), hydroxypropyl methyl cellulose (e.g. Methocel®), liquid glucose, magnesium aluminum silicate, maltodextrin, methylcellulose, polymethacrylates, povidone (e.g. Kollidon®, Plasdone®), pregelatinized starch, sodium alginate and starch.
  • carbomer e.g. carbopol
  • carboxymethylcellulose sodium, dextrin ethyl cellulose
  • gelatin
  • the dissolution rate of a compacted solid pharmaceutical composition in the patient's stomach may be increased by the addition of a disintegrant to the composition.
  • Disintegrants include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g. Ac-Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g. Kollidon®, Polyplasdone®), guar gum, magnesium aluminum silicate, methyl cellulose, microcrystalline cellulose, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate, sodium starch glycolate (e.g. Explotab®) and starch.
  • alginic acid include alginic acid, carboxymethylcellulose calcium, carboxymethylcellulose sodium (e.g. Ac-Di-Sol®, Primellose®), colloidal silicon dioxide, croscarmellose sodium, crospovidone (e.g. Kollidon®, Polyplasdone®
  • Glidants can be added to improve the flowability of a non-compacted solid composition and to improve the accuracy of dosing.
  • Excipients that may function as glidants include colloidal silicon dioxide, magnesium trisilicate, powdered cellulose, starch, talc and tribasic calcium phosphate.
  • a dosage form such as a tablet
  • the composition is subjected to pressure from a punch and dye.
  • Some excipients and active ingredients have a tendency to adhere to the surfaces of the punch and dye, which can cause the product to have pitting and other surface irregularities.
  • a lubricant can be added to the composition to reduce adhesion and ease the release of the product from the dye.
  • Lubricants include magnesium stearate, calcium stearate, glyceryl monostearate, glyceryl palmitostearate, hydrogenated castor oil, hydrogenated vegetable oil, mineral oil, polyethylene glycol, sodium benizoate, sodium lauryl sulfate, sodium stearyl fumarate, stearic acid, talc and zinc stearate.
  • Flavoring agents and flavor enhancers make the dosage form more palatable to the patient.
  • Common flavoring agents and flavor enhancers for pharmaceutical products include maltol, vanillin, ethyl vanillin, menthol, citric acid, fumaric acid, ethyl maltol and tartaric acid.
  • Solid and liquid compositions may also be dyed using any pharmaceutically acceptable colorant to improve their appearance and/or facilitate patient identification of the product and unit dosage level.
  • liquid pharmaceutical compositions of the present invention ziprasidone and any other solid excipients are dissolved or suspended in a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin.
  • a liquid carrier such as water, vegetable oil, alcohol, polyethylene glycol, propylene glycol or glycerin.
  • Liquid pharmaceutical compositions may contain emulsifying agents to disperse uniformly throughout the composition an active ingredient or other excipient that is not soluble in the liquid carrier.
  • Emulsifying agents that may be useful in liquid compositions of the present invention include, for example, gelatin, egg yolk, casein, cholesterol, acacia, tragacanth, chondrus, pectin, methyl cellulose, carbomer, cetostearyl alcohol and cetyl alcohol.
  • Liquid pharmaceutical compositions of the present invention may also contain a viscosity enhancing agent to improve the mouth-feel of the product and/or coat the lining of the gastrointestinal tract.
  • a viscosity enhancing agent include acacia, alginic acid bentonite, carbomer, carboxymethylcellulose calcium or sodium, cetostearyl alcohol, methyl cellulose, ethylcellulose, gelatin guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, polyvinyl alcohol, povidone, propylene carbonate, propylene glycol alginate, sodium alginate, sodium starch glycolate, starch tragacanth and xanthan gum.
  • Sweetening agents such as sorbitol, saccharin, sodium saccharin, sucrose, aspartame, fructose, mannitol and invert sugar may be added to improve the taste.
  • Preservatives and chelating agents such as alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole and ethylenediamine tetraacetic acid may be added at levels safe for ingestion to improve storage stability.
  • a liquid composition may also contain a buffer such as guconic acid, lactic acid, citric acid or acetic acid, sodium guconate, sodium lactate, sodium citrate or sodium acetate. Selection of excipients and the amounts used may be readily determined by the formulation scientist based upon experience and consideration of standard procedures and reference works in the field.
  • a buffer such as guconic acid, lactic acid, citric acid or acetic acid, sodium guconate, sodium lactate, sodium citrate or sodium acetate.
  • the solid compositions of the present invention include powders, granulates, aggregates and compacted compositions.
  • the dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and ophthalmic administration. Although the most suitable administration in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral.
  • the dosages may be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.
  • Dosage forms include solid dosage forms like tablets, powders, capsules, suppositories, sachets, troches and losenges, as well as liquid syrups, suspensions and elixirs.
  • the dosage form of the present invention may be a capsule containing the composition, preferably a powdered or granulated solid composition of the invention, within either a hard or soft shell.
  • the shell may be made from gelatin and optionally contain a plasticizer such as glycerin and sorbitol, and an opacifying agent or colorant.
  • compositions and dosage forms may be formulated into compositions and dosage forms according to methods known in the art.
  • a composition for tableting or capsule filling may be prepared by wet granulation.
  • wet granulation some or all of the active ingredients and excipients in powder form are blended and then further mixed in the presence of a liquid, typically water, that causes the powders to clump into granules.
  • the granulate is screened and/or milled, dried and then screened and/or milled to the desired particle size.
  • the granulate may then be tableted, or other excipients may be added prior to tableting, such as a glidant and/or a lubricant.
  • a tableting composition may be prepared conventionally by dry blending.
  • the blended composition of the actives and excipients may be compacted into a slug or a sheet and then comminuted into compacted granules. The compacted granules may subsequently be compressed into a tablet.
  • a blended composition may be compressed directly into a compacted dosage form using direct compression techniques.
  • Direct compression produces a more uniform tablet without granules.
  • Excipients that are particularly well suited for direct compression tableting include microcrystalline cellulose, spray dried lactose, dicalcium phosphate dihydrate and colloidal silica. The proper use of these and other excipients in direct compression tableting is known to those in the art with experience and skill in particular formulation challenges of direct compression tableting.
  • a capsule filling of the present invention may comprise any of the aforementioned blends and granulates that were described with reference to tableting, however, they are not subjected to a final tableting step.
  • the solid compositions of the present invention include powders, granulates, aggregates and compacted compositions.
  • the dosages include dosages suitable for oral, buccal, rectal, parenteral (including subcutaneous, intramuscular, and intravenous), inhalant and ophthalmic administration. Although the most suitable route in any given case will depend on the nature and severity of the condition being treated, the most preferred route of the present invention is oral.
  • the dosages can be conveniently presented in unit dosage form and prepared by any of the methods well-known in the pharmaceutical arts.
  • the dosage of GEODON may be used as a guidance.
  • the oral dosage form of the present invention is preferably in the form of an oral capsule having a dosage of about 10 mg to about 160 mg, more preferably of about 20 mg to about 80 mg, and most preferably capsules of 20, 40, 60 and 80 mg.
  • X-Ray powder diffraction data were obtained using by method known in the art using a SCINTAG powder X-Ray diffractometer model X'TRA equipped with a solid state detector. Copper radiation of 1.5418 ⁇ was used. A round aluminum sample holder with round zero background quartz plate, with cavity of 25(diameter)*0.5(dept) mm.
  • DSC analysis was done using a Mettler 821 Star e .
  • the weight of the samples was about 5 mg; the samples were scanned at a rate of 10° C./min from 30° C. to 320° C.
  • the oven was constantly purged with nitrogen gas at a flow rate of 40 ml/min. Standard 40 ⁇ l aluminum crucibles covered by lids with 3 holes were used.
  • TGA analysis was done using a Mettler M3 meter.
  • the weight of the samples was about 10 mg; the samples were scanned at a rate of 10° C./min from 25° C. to 200° C.
  • the oven was constantly purged with nitrogen gas at a flow rate of 40 ml/min.
  • Standard 70 ⁇ l alumina crucibles covered by lids with 1 hole were used.
  • IR analysis was done using a Perkin E1 mer SPECTRUM ONE FT-IR spectrometer in DRIFTt mode. The samples in the 4000-400 cm ⁇ 1 interval were scanned 16 times with 4.0 cm ⁇ 1 resolution.
  • the water content of ziprasidone HCl was measured by the methods known in the art like Karl Fisher or thermogravimetric analysis (TGA).
  • TGA thermogravimetric analysis
  • Ziprasidone free base used for preparations of the crystal forms of ziprasidone HCl is characterized by X-Ray peaks at 12.1, 15.2, 16.3, 18.4, 25.0 degrees 2 theta and is further characterized by XRD peaks at 5.2, 10.4, 11.3, 13.1, 21.1, 22.1.
  • the ziprasidone free base has a DSC thermogram like the one shown in FIG. 13 , in which 17 and 120 J/g endothermic peaks can be seen at 92 and 220° C. The first corresponds to dehydration, the second to melting of the ziprasidone free base.
  • the water content of the sample of the base is about 1.2% by weight.
  • the Loss on Drying by TGA is about 2.1% by weight.
  • the IR spectrum of ziprasidone free base is substantially depicted in FIG. 14 .
  • the form of ziprasidone is referred to as Form B.
  • One of skill in the art would appreciate that the processes of the present invention may use other forms of ziprasidone base as starting material.
  • Ziprasidone base for the experiments below was prepared according to the procedure “EXPERIMENT” in U.S. Pat. No. 5,312,925, column 4.
  • the water content of the base was 1.2% (Karl Fisher).
  • Ziprasidone base (50 g) and toluene (250 ml) were charged into a 0.5 L three necked flask. The obtained slurry was heated at 85° C. for 2 hours. The hot slurry was filtrated and the solid was washed with methanol. The solid was dried in air-circulated oven at 50° C. to afford the dried Ziprasidone base form B (by XRD) (45.39 g).
  • Aqueous HCl (37%) (10 ml) was added to a slurry of ziprasidone base Form B (10 g) in acetonitrile (200 ml) at reflux. After the addition, the slurry was heated over night. A solid was filtered and washed with acetonitrile. After drying at 50° C. for ⁇ 16 hours, ziprasidone HCl Form E was obtained (12.71 g) (The water content was 9.25% by K.F. and the loss on drying by TGA is 18.8%), as confirmed by XRD.
  • a slurry of ziprasidone base form B (10 g) in ethyl acetate (100 ml) was heated at reflux without complete dissolution. The slurry was then cooled. When the temperature was about 50° C., aqueous HCl (37%) (10 ml) was added, and the slurry was diluted by addition of ethyl acetate (100 ml). The slurry was stirred for 16 hours. A solid was filtered and washed with ethyl acetate. The wet solid was ziprasidone HCl Form E, as confirmed by XRD. The wet solid was dried at 50° C. The dried solid had a water content of 9.62% (by K.F.) and a loss on drying of 19% (by TGA). The dried solid was Form E, as confirmed by XRD.
  • Aqueous HCl (37%) (10 ml) was added drop-wise to a hot slurry of ziprasidone base Form B (10 g) in methylethylketone (MEK) (200 ml). The slurry was stirred at room temperature over night. A solid was filtered and washed with MEK. The wet solid was ziprasidone HCl Form F. The wet solid was dried at 50° C. for two days. The dried product was ziprasidone HCl Form F (10.62 g) (The water content was 3.87% by K.F. and the loss on drying is 4.1% by TGA), as confirmed by XRD.
  • Aqueous hydrochloric acid (37%) (910 ml) was added to a hot slurry of ziprasidone base (10 g) in tetrahydrofuran (THF) (200 ml). The slurry was stirred at room temperature for about 16 hours. A solid was filtered, washed with THF and dried in an oven at 50° C. for two days. The wet and the dried solid samples were ziprasidone HCl Form F (The water content was 3.63%), as confirmed by XRD.
  • Ziprasidone base (10 g) was dissolved in dimethylacetamide (100 ml) at ⁇ 95° C. The solution was cooled to 70° C. and aqueous HCl (37%) (10 ml) was added, resulting in precipitation and formation of a slurry. The slurry was then cooled to room temperature, followed by addition of water (100 ml). Stirring was continued for 1 hour at room temperature, followed by filtration, and washing of a solid material obtained from filtration with water. The wet solid was dried at 50° C. for about 16 hours to a dry solid (7.1 g). The wet and the dried solid were ziprasidone HCl Form F in mixture with Form M (The water content of the dried solid is 4.17% by K.F.), as confirmed by XRD.
  • Ziprasidone hydrochloride Form E (4.05 g) was heated at 80-105° C. in an oven for about 16 hours. The solid after heating was ziprasidone HCl amorphous (3.33 g) (The water content was 1.21% by K.F.), as confirmed by XRD.
  • Ziprasidone base (10 g) was taken in dimethylcarbonate (DMC) (100 ml) and the mixture was heated at ⁇ 90° C. Aqueous HCl (37%) (10 ml) was added, resulting in a sticky material. Additional amount of DMC (100 ml), and methanol (50 ml), were added, resulting in a slurry. The slurry was stirred at room temperature over night. A solid was filtered and washed with DMC, and subsequently dried at 50° C. overnight. The wet and the dried solids were ziprasidone HCl monohydrate, as confirmed by XRD. The water content of the dried solid by K.F. is 4.78%.
  • drying was carried out in an air-circulated oven.
  • the pressure was atmospheric pressure.
  • Ziprasidone base Form B (10 g) was added to ethyl-lactate (50 ml) and the slurry obtained was cooled to 5° C. HCl (g) was bubbled through the above slurry and ether (150 ml) was added. The slurry was stirred over night at room temperature, filtrated and washed with ether. The wet material was dried at 50° C. in an air-circulated oven and ziprasidone HCl Form G was obtained.
  • Ziprasidone base Form B (5 g) was added to carbon-tetrachloride (50 ml) and HCl(g) was bubbled until pH 1 was reached. The temperature rose to ⁇ 40° C. The slurry was stirred at room temperature for 3 hours and filtrated. The solid was dried in an air-circulated oven at 50° C. for 17 hours. The wet and the dried solid both were ziprasidone HCl Form G.
  • Ziprasidone base Form B (10 g) was added to di-iso-propyl-ether (200 ml) and the slurry was stirred at room temperature; through the slurry HCl(g) was bubbled while the temperature rose to 50° C. The slurry was stirred at room temperature over-night, the solid was filtrated and washed with di-iso-propyl-ether. The wet solid gave ziprasidone HCl Form G. Drying of the wet solid in an air-circulated oven at 50° C. for ⁇ 16 h gave ziprasidone HCl Form I.
  • Ziprasidone base Form B (log) was added to ethyl-acetate (200 ml) and HCl(g) was bubbled through the slurry; the temperature rose to ⁇ 35° C. The slurry was stirred at room temperature for 3 hours and the solid was filtrated, washed with ethyl-acetate and dried for ⁇ 16 h in an air-circulated oven at 45° C. The wet and dried solids both gave a mixture of ziprasidone HCl Form G and F.
  • ziprasidone base (Form B) (10 g) in methanol (100 ml) at ⁇ 5° C. was bubbled HCl (g); the obtained slurry was then stirred over night at room temperature. A solid was filtrated, washed with methanol and dried at 50° C. for about 16 hours. The product was ziprasidone HCl Form M (KF. 4.5%).
  • ziprasidone base Form B (log) (log) in methanol (200 ml) at 60° C. was added concentrated HCl (10 ml); the slurry was then stirred at room temperature for about 16 hours. A solid was filtrated, washed with methanol (2 ⁇ 10 ml) and dried at 50° C. in an air-circulated oven for 2 days.
  • the product was ziprasidone HCl Form M (K.F. 4.26%).
  • a slurry of ziprasidone base (Form B) (10 g) in n-butanol (250 ml) was heated to 60° C. While maintaining the temperature, concentrated HCl was added (10 ml). The reaction mixture was than stirred at room temperature for about 16 hours. A solid was filtrated, washed with n-butanol (2 ⁇ 20 ml) and dried for about 16 hours at 50° C. in an air-circulated oven. The dried solid was ziprasidone HCl Form M (K.F. 4.12%).
  • Ziprasidone HCl Form E (2 g) was heated in n-butanol (200 ml) and water (40 ml) at 85° C.; complete dissolution was not obtained. More water was added (20 ml) and the slurry was stirred at 90° C. for 1.5 hours. A solid was filtrated from the hot slurry, washed with n-butanol/water (4 ml 3:1) and dried. From the filtrate a solid was obtained upon cooling to 10° C. This material was filtrated, washed and dried in the same conditions. Both dried solids were ziprasidone HCl Form M.
  • Aqueous HCl was drop-wise added over 10 minutes, to a slurry of ziprasidone base (5 g) in toluene (100 ml) at room temperature. The obtained mixture was stirred at room temperature for 3 hours, and then the solvent was evaporated under vacuum. The solid obtained after the toluene evaporation was ziprasidone HCl Form J.
  • the above material (ZPR HCl form J) was dried by maintaining it at 40° C. and under nitrogen over night, followed by an additional drying operation on a rotary evaporator.
  • the dried material collected in the two drying stages was ziprasidone HCl Form E1 (water content by K.F. 6% and 7.8% respectively).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
US10/860,926 2003-06-03 2004-06-03 Polymorphic forms of ziprasidone HCI and processes for their preparation Abandoned US20050043324A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/860,926 US20050043324A1 (en) 2003-06-03 2004-06-03 Polymorphic forms of ziprasidone HCI and processes for their preparation
US11/999,453 US20080091020A1 (en) 2003-06-03 2007-12-03 Polymorphic forms of ziprasidone HCI and processes for their preparation
US11/999,337 US20080090835A1 (en) 2003-06-03 2007-12-03 Polymorphic forms of ziprasidone HCl and processes for their preparation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47580603P 2003-06-03 2003-06-03
US48791303P 2003-07-16 2003-07-16
US49497003P 2003-08-13 2003-08-13
US52834603P 2003-12-09 2003-12-09
US57199704P 2004-05-17 2004-05-17
US10/860,926 US20050043324A1 (en) 2003-06-03 2004-06-03 Polymorphic forms of ziprasidone HCI and processes for their preparation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/999,337 Division US20080090835A1 (en) 2003-06-03 2007-12-03 Polymorphic forms of ziprasidone HCl and processes for their preparation
US11/999,453 Division US20080091020A1 (en) 2003-06-03 2007-12-03 Polymorphic forms of ziprasidone HCI and processes for their preparation

Publications (1)

Publication Number Publication Date
US20050043324A1 true US20050043324A1 (en) 2005-02-24

Family

ID=34199327

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/860,926 Abandoned US20050043324A1 (en) 2003-06-03 2004-06-03 Polymorphic forms of ziprasidone HCI and processes for their preparation
US10/860,864 Expired - Fee Related US7678799B2 (en) 2003-06-03 2004-06-03 Crystalline ziprasidone HCl and processes for preparation thereof
US11/804,301 Abandoned US20070238738A1 (en) 2003-06-03 2007-05-16 Crystalline ziprasidone HCI and processes for preparation thereof
US11/999,337 Abandoned US20080090835A1 (en) 2003-06-03 2007-12-03 Polymorphic forms of ziprasidone HCl and processes for their preparation
US11/999,453 Abandoned US20080091020A1 (en) 2003-06-03 2007-12-03 Polymorphic forms of ziprasidone HCI and processes for their preparation

Family Applications After (4)

Application Number Title Priority Date Filing Date
US10/860,864 Expired - Fee Related US7678799B2 (en) 2003-06-03 2004-06-03 Crystalline ziprasidone HCl and processes for preparation thereof
US11/804,301 Abandoned US20070238738A1 (en) 2003-06-03 2007-05-16 Crystalline ziprasidone HCI and processes for preparation thereof
US11/999,337 Abandoned US20080090835A1 (en) 2003-06-03 2007-12-03 Polymorphic forms of ziprasidone HCl and processes for their preparation
US11/999,453 Abandoned US20080091020A1 (en) 2003-06-03 2007-12-03 Polymorphic forms of ziprasidone HCI and processes for their preparation

Country Status (6)

Country Link
US (5) US20050043324A1 (fr)
EP (2) EP1530570A2 (fr)
KR (4) KR20080022595A (fr)
CA (2) CA2528192A1 (fr)
IL (2) IL172005A0 (fr)
WO (2) WO2005035531A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005100348A1 (fr) * 2004-04-15 2005-10-27 Lupin Limited Hydrochlorure de ziprasidone amorphe
US20060205947A1 (en) * 2005-03-11 2006-09-14 Rey Allan W Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2338534T3 (es) 2001-02-27 2010-05-10 The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services Analogos de talidomina como inhibidores de la angiogenesis.
ES2334800T3 (es) 2004-02-27 2010-03-16 Ranbaxy Laboratories Limited Proceso para la preparacion de ziprasidona.
ITMI20040944A1 (it) * 2004-05-11 2004-08-11 Dinamite Dipharma S P A In For Polimorfo di ziprasidone cloridrato e procedimento per la sua preparazione
CA2467538C (fr) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. Nouveau chlorhydrate de ziprasidone amorphe (chlorhydrate de 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydr o-2h-indol-2-one) et procedes pour sa production
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
ITMI20050346A1 (it) * 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
KR100989389B1 (ko) * 2010-06-15 2010-10-25 화일약품주식회사 새로운 결정형을 갖는 지프라시돈 염산염 및 이의 제조방법
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
WO2013071272A1 (fr) * 2011-11-11 2013-05-16 Intellikine, Llc Polymorphes d'inhibiteur de kinase
AU2014348523B2 (en) 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
US20250049709A1 (en) * 2021-12-11 2025-02-13 Beloteca, Inc. Ziprasidone formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US20050143396A1 (en) * 2003-04-11 2005-06-30 Hertero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
JPH0680874A (ja) 1992-08-31 1994-03-22 Nippon G Ii Plast Kk 熱可塑性ポリエステルエラストマー樹脂組成物
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
US6110918A (en) * 1996-05-07 2000-08-29 Pfizer Inc Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
CZ20011726A3 (cs) * 2000-05-26 2002-02-13 Pfizer Products Inc. Způsob reakční krystalizace, který umoľňuje řídit velikost částic
WO2003063822A2 (fr) * 2002-02-01 2003-08-07 Pfizer Products Inc. Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen d'un appareil de sechage par pulverisation modifie
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
WO2004050655A1 (fr) 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Formes polymorphes de ziprasidone et son chlorhydrate
CN1255105C (zh) 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
RU2334153C2 (ru) 2003-01-29 2008-09-20 Фишер Контролз Интернэшнл Ллс Индикатор перемещения клапана

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US20050143396A1 (en) * 2003-04-11 2005-06-30 Hertero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005100348A1 (fr) * 2004-04-15 2005-10-27 Lupin Limited Hydrochlorure de ziprasidone amorphe
US20060205947A1 (en) * 2005-03-11 2006-09-14 Rey Allan W Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006094396A1 (fr) * 2005-03-11 2006-09-14 Apotex Pharmachem Inc. Preparation de sels d'addition acides de ziprasidone et intermediaires de ceux-ci a l'aide de reactions en phase solide-phase gazeuse
EP1856115A4 (fr) * 2005-03-11 2010-01-06 Apotex Pharmachem Inc Preparation de sels d'addition acides de ziprasidone et intermediaires de ceux-ci a l'aide de reactions en phase solide-phase gazeuse
US7745624B2 (en) 2005-03-11 2010-06-29 Apotex Pharma Chem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions

Also Published As

Publication number Publication date
US20070238738A1 (en) 2007-10-11
WO2005016325A2 (fr) 2005-02-24
EP1546146A1 (fr) 2005-06-29
KR20060024788A (ko) 2006-03-17
IL172004A0 (en) 2009-02-11
US20050059680A1 (en) 2005-03-17
KR100880279B1 (ko) 2009-01-28
US20080090835A1 (en) 2008-04-17
CA2528192A1 (fr) 2005-02-24
IL172005A0 (en) 2009-02-11
KR20080022595A (ko) 2008-03-11
US20080091020A1 (en) 2008-04-17
WO2005035531A1 (fr) 2005-04-21
KR20080093164A (ko) 2008-10-20
WO2005016325A3 (fr) 2005-03-24
CA2528100A1 (fr) 2005-04-21
KR20060015750A (ko) 2006-02-20
EP1530570A2 (fr) 2005-05-18
US7678799B2 (en) 2010-03-16

Similar Documents

Publication Publication Date Title
US20080091020A1 (en) Polymorphic forms of ziprasidone HCI and processes for their preparation
US20080091017A1 (en) Polymorphic form B2 of ziprasidone base
US20080097096A1 (en) Processes for preparation of crystalline mycophenolate sodium
US20060155119A1 (en) Ascomycin crystalline forms and preparation thereof
US20210387952A1 (en) Solid state forms of daprodustat and process for preparation thereof
US20250263380A1 (en) Solid state forms of mitapivat and process for preparation thereof
US20050165085A1 (en) Polymorphic forms of tegaserod base and salts thereof
US20240391916A1 (en) Solid state forms of ensifentrine and process for preparation thereof
US12492213B2 (en) Solid state forms of sep-363856 and process for preparation thereof
US20040229896A1 (en) Stable pharmaceutical compositions of desloratadine
US12441701B2 (en) Solid state forms of roluperidone and salts thereof
US12404267B2 (en) Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]phenyl}-2H-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4H-chromene-2-carboxamide and of its mesylate salt
US20250276959A1 (en) Solid state forms of zavegepant hydrochloride and process for preparation thereof
US20250250239A1 (en) Solid state forms of mavacamten and process for preparation thereof
US20220153744A1 (en) Solid state forms of acalabrutinib
US20240368094A1 (en) Polymorphs of ponesimod
US20250154158A1 (en) Solid state forms of seltorexant
US20220380288A1 (en) Solid state forms of fezagepras and process for preparation thereof
US20230357163A1 (en) Solid state forms of gefapixant and process for preparation thereof
US20210395193A1 (en) New crystalline polymorphs of rigosertib sodium
WO2024261740A1 (fr) Formes à l'état solide de sunvozertinib

Legal Events

Date Code Title Description
AS Assignment

Owner name: TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOLTAI, TAMAS;HEDVATI, LILACH;MENDELOVICI, MARIOARA;AND OTHERS;REEL/FRAME:015332/0741;SIGNING DATES FROM 20040922 TO 20040928

Owner name: TEVA PHARMACEUTICALS USA, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF RIGHTS IN BARBADOS;ASSIGNOR:TEVA PHARMACEUTICAL INDUSTRIES LTD.;REEL/FRAME:015332/0859

Effective date: 20040829

AS Assignment

Owner name: TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOLTAI, TAMAS;HEDVATI, LILACH;MENDELOVICI, MARIOARA;AND OTHERS;REEL/FRAME:020247/0696;SIGNING DATES FROM 20040922 TO 20040928

Owner name: TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOLTAI, TAMAS;HEDVATI, LILACH;MENDELOVICI, MARIOARA;AND OTHERS;REEL/FRAME:020247/0738;SIGNING DATES FROM 20040922 TO 20040928

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION